411 related articles for article (PubMed ID: 12532382)
1. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
Maa YF; Zhao L; Payne LG; Chen D
J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382
[TBL] [Abstract][Full Text] [Related]
2. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.
Maa YF; Shu C; Ameri M; Zuleger C; Che J; Osorio JE; Payne LG; Chen D
Pharm Res; 2003 Jul; 20(7):969-77. PubMed ID: 12880281
[TBL] [Abstract][Full Text] [Related]
3. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment.
Maa YF; Ameri M; Shu C; Zuleger CL; Che J; Osorio JE; Payne LG; Chen D
Curr Drug Deliv; 2007 Jan; 4(1):57-67. PubMed ID: 17269918
[TBL] [Abstract][Full Text] [Related]
5. Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application.
Maa YF; Ameri M; Rigney R; Payne LG; Chen D
Pharm Res; 2004 Mar; 21(3):515-23. PubMed ID: 15070104
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.
Maa YF; Ameri M; Shu C; Payne LG; Chen D
J Pharm Sci; 2004 Jul; 93(7):1912-23. PubMed ID: 15176078
[TBL] [Abstract][Full Text] [Related]
7. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars.
Tonnis WF; Amorij JP; Vreeman MA; Frijlink HW; Kersten GF; Hinrichs WL
Eur J Pharm Sci; 2014 May; 55():36-45. PubMed ID: 24468629
[TBL] [Abstract][Full Text] [Related]
8. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
[TBL] [Abstract][Full Text] [Related]
9. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
10. Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability.
Sonner C; Maa YF; Lee G
J Pharm Sci; 2002 Oct; 91(10):2122-39. PubMed ID: 12226840
[TBL] [Abstract][Full Text] [Related]
11. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine.
Clausi A; Cummiskey J; Merkley S; Carpenter JF; Braun LJ; Randolph TW
J Pharm Sci; 2008 Dec; 97(12):5252-62. PubMed ID: 18398901
[TBL] [Abstract][Full Text] [Related]
12. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
[TBL] [Abstract][Full Text] [Related]
13. Bioneedles as alternative delivery system for hepatitis B vaccine.
Hirschberg HJ; van de Wijdeven GG; Kraan H; Amorij JP; Kersten GF
J Control Release; 2010 Oct; 147(2):211-7. PubMed ID: 20620183
[TBL] [Abstract][Full Text] [Related]
14. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.
Singh M; Ugozzoli M; Kazzaz J; Chesko J; Soenawan E; Mannucci D; Titta F; Contorni M; Volpini G; Del Guidice G; O'Hagan DT
Vaccine; 2006 Mar; 24(10):1680-6. PubMed ID: 16300864
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
[TBL] [Abstract][Full Text] [Related]
16. Development of (Inhalable) Dry Powder Formulations of AS01
AboulFotouh K; Xu H; Moon C; Williams RO; Cui Z
Int J Pharm; 2022 Jun; 622():121825. PubMed ID: 35577037
[TBL] [Abstract][Full Text] [Related]
17. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
18. Spray freeze drying for dry powder inhalation of nanoparticles.
Ali ME; Lamprecht A
Eur J Pharm Biopharm; 2014 Aug; 87(3):510-7. PubMed ID: 24657824
[TBL] [Abstract][Full Text] [Related]
19. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.
Thakkar SG; Ruwona TB; Williams RO; Cui Z
Hum Vaccin Immunother; 2017 Apr; 13(4):936-946. PubMed ID: 28051903
[TBL] [Abstract][Full Text] [Related]
20. Developments in the formulation and delivery of spray dried vaccines.
Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
